After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

Scientists comment on the FDA approving Cobenfy (KarXT) for schizophrenia. Dr Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis, Consultant Psychiatrist, King’s College, ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...